CenterBook Partners
GENB icon

CenterBook Partners’s Generate Biomedicines GENB Stock Holding History

CenterBook Partners’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$651K Sell
43,373
-88,187
-67% -$1.36M 0.03% 556
2026
Q2 		$2.22M Sell
131,560
-135,253
-51% -$1.84M 0.11% 211
2026
Q1 		$3.34M Buy
+266,813
New +$3.26M 0.18% 150

Other funds holding GENB

Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Savant Capital
Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Bank Pictet & Cie (Europe)
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dynamic Advisor Solutions
Dynamic Advisor Solutions Phoenix, Arizona $3.52B AUM 15.33% 1-Year Est. Return
Magnus Financial Group
Magnus Financial Group New York $1.5B AUM 16.47% 1-Year Est. Return

CenterBook Partners's GENB Position: Q3 2026 in Review

CenterBook Partners reduced its Generate Biomedicines (GENB) stake by 67% in Q3 2026, selling an estimated $1.36M and leaving 43,373 shares worth $651K. The position accounts for 0.03% of the portfolio, ranked #556.

CenterBook Partners first reported a position in GENB in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.34M in Q1 2026. 35 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

  • CenterBook Partners held 43,373 shares of Generate Biomedicines worth $651K as of Q3 2026.
  • CenterBook Partners sold 88,187 Generate Biomedicines shares in Q3 2026, an estimated $1.36M.
  • Generate Biomedicines made up 0.03% of CenterBook Partners's portfolio in Q3 2026, its #556 holding.
  • CenterBook Partners first reported a position in Generate Biomedicines in Q1 2026 and has held it in 3 quarters since.
  • CenterBook Partners's Generate Biomedicines position peaked at $3.34M in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.